. O'Sullivan.
"Literally, the patient comes into the procedure with difficulty or cannot
walk and I can now walk them out of the procedure room at the end of the
treatment. These patients are typically back to work in 2-3 days versus the
6-8 weeks with anticoagulation-only treatment."
About Bacchus Vascular
Bacchus Vascular, Inc. is a privately held medical device company
dedicated to the treatment of peripheral vascular disease. Dr. Thomas
Fogarty, a noted inventor and cardiovascular surgeon, founded the company
with the vision of transforming blood clot removal from peripheral blood
vessels into a fast, simple, minimally-invasive catheter-based procedure.
Thousands of patients suffering from DVT and other occlusive vascular
diseases have been treated worldwide to date using the company's Trellis(R)
Peripheral Infusion System and other products.
For more information, visit http://www.bacchusvascular.com
'/>"/>SOURCE Bacchus Vascular, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine technology :1.
Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective2.
YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter3.
Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call4.
Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium5.
Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial6.
Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion7.
New Deep Vein Thrombosis (DVT) Registry Data Show Clot Quickly Removed, Blood Flow Restored in Large Patient Registry8.
Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay9.
American Heart Association Journal Report: Reducing Kids Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks10.
Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control11.
Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells